Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 19/20 | 0.57 |
| ▸ | GPR183 | P32249 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10067695 | 0.90 | GPR119 (0.50) | GPR119GPR183KCNH2CYP3A4CYP2C19 | |
| SCHEMBL903917 | 0.88 | GPR119 (0.60) | GPR119GPR183KCNH2CYP3A4CYP2C19 | |
| SCHEMBL10068004 | 0.87 | GPR119 (0.54) | GPR119GPR183KCNH2CYP3A4CYP2C19 | |
| SCHEMBL904156 | 0.82 | GPR119 (0.62) | GPR119GPR183KCNH2CYP3A4CYP2C19 | |
| SCHEMBL388889 | 0.80 | GPR119 (0.83) | GPR119GPR183KCNH2CYP3A4CYP2C19 | |
| SCHEMBL903997 | 0.76 | GPR119 (0.66) | GPR119GPR183KCNH2CYP3A4CYP2C19 | |
| SCHEMBL903998 | 0.74 | GPR119 (0.68) | GPR119GPR183KCNH2CYP3A4CYP2C19 | |
| SCHEMBL904055 | 0.74 | GPR119 (0.68) | GPR119GPR183KCNH2CYP3A4CYP2C19 | |
| SCHEMBL10067782 | 0.74 | GPR119 (0.68) | GPR119GPR183KCNH2CYP3A4CYP2C19 | |
| SCHEMBL389359 | 0.74 | GPR119 (0.81) | GPR119GPR183KCNH2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012041158-A1 | TRICYCLIC COMPOUND, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2012-04-05 | — | — | WO | disclosed |